A Phase 4 Pilot Study With Extension to Assess the Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease and the Effect on Corneal Nerves and Neuropathic Corneal Pain

Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component. At least 16 patients will receive and complete 12 weeks of 80 units of Acthar Gel to be injected subcutaneously twice weekly via Acthar Gel single-dose pre-filled SelfJectTM injector (SelfJect) to assess the effects on subjective sensation of ocular pain, conjunctival and corneal staining, in vivo assessments of corneal nerves as measured by confocal imaging, VAS scales of common neuropathic pain symptoms and comfort of SelfJect will be assessed.

开始日期2025-02-11

申办/合作机构

Toyos Clinic

ChiCTR2400090753

/ SuspendedN/AIIT

Diagnostic Value of ACTH Stimulation Test under 1mg dexamethasone suppression test in differentiating the Subtypes of Primary Aldosteronism

开始日期2024-10-15

申办/合作机构-

CTRI/2024/06/069346

/ Not yet recruiting临床4期IIT

A comparison of Porcine Sequence Corticotropin to Tetracosactide Hexaacetate on stimulated 17 Hydroxyprogesterone levels in healthy individuals. - NIL

开始日期2024-07-01

申办/合作机构-

100 项与促皮质素相关的临床结果

登录后查看更多信息

100 项与促皮质素相关的转化医学

登录后查看更多信息

100 项与促皮质素相关的专利（医药）

登录后查看更多信息

6,471

项与促皮质素相关的文献（医药）

2025-06-01·Neurology and Therapy

Factors Influencing the Response of Patients with Infantile Epileptic Spasms Syndrome to ACTH as Repeated First-Line Therapy

Article

作者: Pang, Ping ; Zhang, Ziyan ; Wan, Lin ; Ge, Wenrong ; Yang, Guang

INTRODUCTION:

The treatment of infantile epileptic spasms syndrome (IESS) aims to achieve spasm control. Current first-line interventions include hormone therapy (adrenocorticotropic hormone [ACTH] and corticosteroids) and vigabatrin. Despite treatment, the response rate remains at around 40%, with some infants experiencing relapse after achieving initial spasm control. In certain cases, a second course of first-line therapy may be warranted. The objective of this study was to perform a secondary analysis of data from our previously published studies to elucidate factors influencing the efficacy of ACTH following its re-administration after the lack of response to the initial first-line treatment or relapse.

METHODS:

We conducted a retrospective analysis of clinical data from children with IESS who had experienced treatment failure or relapse following initial first-line therapy and who subsequently received ACTH at our institution as a second first-line treatment. We examined such variables as etiological classification, interval between treatments, age at first epileptic seizure, radiological findings, and changes in pharmacological treatment modalities, with the overall aim to assess the impact of these variables on the short-term response (disappearance of spasms for > 4 weeks and without hypsarrhythmia pattern) to the second administration of the first-line therapy.

RESULTS:

Among the 128 patients with IESS identified and included in the analysis, 50 (39.1%) achieved a short-term response. Comparative analysis indicated that responders had a shorter duration between the initial first-line therapy and the initiation of the second first-line treatment (median 1.00 [interquartile range {IQR} 0.00, 2.00] vs. 1.75 [IQR 0.50, 3.88] months), were younger at the time of the second first-line treatment (median 11 [IQR 8, 17] vs. 16 [IQR 10, 24] months, p = 0.008), and were less likely to present with additional seizure types during spasm episodes (12.0% vs. 28.2%, p = 0.030). A multifactorial regression model indicated that older age at first seizure and a short-term response to initial first-line treatment were associated with a higher likelihood of obtaining an initial response in the subsequent ACTH treatment (odds ratio [OR] 2.69, 95% confidence interval [CI] 1.39, 7.23, p = 0.014 and OR 5.41, 95% CI 1.48, 23.90, p = 0.016, respectively). Conversely, an older age at the time of the initial first-line treatment, an older age at the onset of epileptic spasms, and patients with congenital structural abnormalities without genetic abnormalities were less likely to achieve an initial response in subsequent ACTH treatment (OR 0.85, 95% CI 0.78, 0.92, p < 0.001; OR 0.43, 95% CI 0.16, 0.82, p = 0.032; and OR 0.18, 95% CI 0.04, 0.69, p = 0.016, respectively)..

CONCLUSION:

A second ACTH therapy regimen (second first-line treatment) may help some children with IESS who did not respond to the initial treatment or who subsequently relapsed, with one-third of patients responding in the short-term. Congenital anomalies without genetic abnormalities and older spasm onset age lessen the odds of response, while younger age at ACTH re-treatment could improve these. ACTH may be reconsidered after initial treatment response followed by relapse.

2025-04-01·NEUROPEDIATRICS

Pulsatile Dexamethasone in Patients with Infantile Spasms: A Retrospective Analysis of a Unique Therapy Regime

Article

作者: Brandl, Ulrich ; Reimer, Dennis ; Vries, Heike De

Abstract:

Objective Infantile spasms (IS) are an age-specific epilepsy syndrome associated with poor outcomes. Sustained and early spasm control remains the main goal of therapy. We aimed to evaluate a unique pulsatile dexamethasone therapy regime in children with IS. Methods Children with IS were treated with oral pulsatile-applied dexamethasone in the Children's Hospital Jena between 2002 and 2021, regardless of duration since IS onset or previous therapy (except ACTH). A prolonged initial pulse was given in case of insufficient response (standard: 5–7 days, prolonged: 10–14 days). We analyzed spasm reduction, electroencephalographic response, adverse reactions, neurodevelopmental status, and epileptic disorders at the last follow-up. Results Included were 26 patients with a median age of 5.5 months (interquartile range 4–8) at IS onset and a mean follow-up of 6.2 years (standard deviation [SD] 3.99). Fifty percent had an unknown etiology. Patients received on average 10.8 pulses (SD 6.0); 69.2% achieved initial seizure freedom, however, 38.9% relapsed. Seventeen patients had an initial prolonged pulse, of those, 14 got initially seizure-free (82.4%). Sixty-four percent of the cases had a sustained spasm cessation after the third pulse. At the last follow-up, half of the patients had no persisting epileptic disorder; 22.2% had a favorable neurocognitive development. Patients with unknown etiology were more likely to achieve seizure freedom during therapy (p = 0.025), had a more favorable neurocognitive outcome (p = 0.049), and were less likely to suffer from epileptic disorders (p = 0.037). No serious adverse effects were observed. Conclusion Our results show that our treatment is safe and leads to outcomes comparable to usually applied hormonal therapy regimes. Etiology remains the most influential factor.

2025-04-01·EPILEPSY & BEHAVIOR

Efficacy of ACTH therapy in children with Landau-Kleffner Syndrome and Autism Spectrum Disorder: A retrospective analysis

Article

作者: Sever, Ali ; Onder, Alparslan ; Muduroglu-Kirmizibekmez, Aynur ; Altunel, Attila ; Altunel, Ozlem ; Kara, Ihsan

BACKGROUND:

Landau-Kleffner Syndrome (LKS) and Autism Spectrum Disorder (ASD), both neurodevelopmental disorders, are frequently associated with epileptic seizures and characteristic epileptiform activity. Electrical Status Epilepticus during Sleep (ESES) is commonly observed in LKS, while Interictal Epileptiform Discharges (IEDs) are typical in ASD. Adrenocorticotropic hormone (ACTH) treatment has demonstrated the potential to reduce the indexes of these related discharges and the number of seizures.

OBJECTIVE:

This retrospective study aimed to assess the response to ACTH treatment in children diagnosed with LKS or ASD, both with and without epileptic seizures.

METHODS:

The study included 236 children, with separate analyses performed for those diagnosed with LKS or ASD. EEG recordings and treatment outcomes were retrospectively evaluated. Key assessments included changes in the indexes of ESES and IED, seizure control rates, and reported side effects.

RESULTS:

ACTH treatment led to significant improvements in indexes and seizure control in both LKS and ASD populations. In children with LKS and epileptic seizures, the mean ESES index reduction was 49.9 % (±17.7), with 50 % achieving complete seizure control. For children with ASD and epileptic seizures, the mean IED index reduction was 47.2 % (±16.7), with 41 % achieving complete seizure control. Rare side effects were transient and reversible, with no reports of serious adverse events.

CONCLUSION:

ACTH treatment demonstrates efficacy in reducing ESES and IED indexes and controlling seizures in children with LKS and ASD. These findings underscore the importance of early intervention and careful management of side effects in optimizing outcomes for these patient populations.

项与促皮质素相关的新闻（医药）

2025-05-16

·PRNewswire

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (crinecerfont) for up to one year. In addition, the study showed that for patients on CRENESSITY, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decreased glucocorticoid doses. Results also showed improvements in clinical outcomes, including body mass index and insulin resistance. These data will be presented at the Pediatric Endocrine Society (PES) 2025 Annual Meeting taking place from May 15-18, 2025, in National Harbor, MD. "These results demonstrate that CRENESSITY has the potential to transform the treatment landscape for children and adolescents living with classic congenital adrenal hyperplasia," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "By simultaneously addressing the underlying hormonal imbalances and allowing for a reduction in glucocorticoid doses, we're seeing improvements in clinical outcomes, including reductions in body mass index and insulin resistance." The Phase 3 CAHtalyst Pediatric study was part of the largest-ever interventional clinical trial program in classic congenital adrenal hyperplasia (CAH) including 103 pediatric patients, four to 17 years of age. The trial consisted of a 28-week, double-blind, placebo-controlled (DBPC) period, during which patients with classic CAH on supraphysiologic glucocorticoid (GC) doses were randomized 2:1 to receive CRENESSITY or placebo, and a 24-week, open-label (OL) period, during which all patients received CRENESSITY. During both the DBPC and OL periods, GC doses were kept stable for the first four weeks and then decreased as tolerated toward more physiologic levels while maintaining or improving androstenedione (A4) relative to Day 1 baseline. Three separate analyses examined the effect of CRENESSITY on: Changes in serum A4 levels and GC doses. Changes in adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP) levels. Clinical outcomes. Long-term, sustained reductions in high GC doses, in addition to improvements in key clinical outcomes, were observed in pediatric patients with up to one year of treatment with CRENESSITY: Reductions in supraphysiologic GC doses observed with 28 weeks of treatment with CRENESSITY were maintained during long-term treatment of up to one year. Importantly, for patients who were randomized to CRENESSITY during the DBPC period, the proportion who achieved a GC dose within the physiologic range (i.e., ≤11 mg/m2/d hydrocortisone equivalents) was stable from Week 28 (30%) to Week 52 (32%). Pre-glucocorticoid ACTH, 17-OHP and A4 levels were reduced to below Day 1 baseline levels in children and adolescents with classic CAH taking CRENESSITY for up to one year, even after significant reductions in GC dose. Improvements were observed in body mass index (BMI) and insulin resistance in children and adolescents with classic CAH taking CRENESSITY for up to one year. In addition, hirsutism in female participants did not worsen, despite significant reductions in GC dose. CRENESSITY was generally well tolerated, with no adrenal crises reported in the DBPC period. The most common adverse reactions with CRENESSITY were headache (25% versus 6% for placebo), abdominal pain (13% versus 0%), fatigue (7% versus 0%), nasal congestion (7% versus 3%) and epistaxis (4% versus 0%). GC Dosing Regimens in the Phase 3 CAHtalyst™ Adult and CAHtalyst Pediatric Studies Additional data will be presented regarding changes in GC regimens in both adult and pediatric patients with classic CAH. Hydrocortisone dosing frequency was more likely to decrease with CRENESSITY, as was switching to dexamethasone- and prednisolone-free regimens. These changes may reduce both the CAH treatment burden and the risk of adverse effects of chronic treatment with high-dose GCs. Additional poster pr esentations at the PES 2025 Annual Meeting include: Treatment Patterns and Changes in Health States in Pediatric Patients with Classic Congenital Adrenal Hyperplasia: An Analysis of Data from the CAHtalog™ Registry Crinecerfont Enables Reduction of Glucocorticoid Doses While Maintaining or Improving Androstenedione in Pediatric Patients with Classic Congenital Adrenal Hyperplasia: Subgroup Analyses from the CAHtalyst™ Pediatric Phase 3 Study Crinecerfont Allows for More Physiologic Glucocorticoid Treatment with Greater Reductions of Androstenedione in Pediatric Patients with Classic Congenital Adrenal Hyperplasia: Analyses of Individual Patient Data from the CAHtalyst™ Pediatric Study About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase. Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used to correct the endogenous cortisol deficiency, but doses higher than those for cortisol replacement (supraphysiologic) are needed to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs) or ovarian adrenal rest tumors (OARTs). About The CAHtalyst™ Pediatric Study The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever interventional clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITY™ (crinecerfont) CRENESSITY is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including: Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL. Please see full Prescribing Information. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook. (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY, CAHtalyst and CAHtalog are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2025. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2025 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-CFT-US-0027 05/2025 SOURCE Neurocrine Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期

2025-05-15

·EINPresswire

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL. One presentation is a post-hoc analysis showing investigational candidate paltusotine provided rapid and durable treatment effects and was well tolerated in surgically naïve patients with acromegaly. The second presentation on symptom variability in acromegaly shows the significant disease burden that patients on long-acting injectable somatostatin analogs can experience. Additionally, one other acromegaly abstract – a real-world evidence analysis revealing high discontinuation rates with the existing standard-of-care treatment – and one abstract on investigational candidate atumelnant will be included in an AACE supplemental journal publication following the meeting. The atumelnant abstract features new data from a Phase 1b/2a study that provides insights into hydrocortisone administration and cortisol monitoring in patients with adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome. “We believe our lead development candidate, paltusotine, has the potential to deliver meaningful improvements for people living with acromegaly, and are encouraged by recent progress in both the U.S. and EU where regulatory reviews of its proposed use remain on track,” said Dana Pizzuti, M.D., Chief Medical and Development Officer, Crinetics. “As we prepare for a PDUFA action date of September 25 in the U.S., the research we’re presenting and publishing at AACE this year reinforces the potential for this novel, once-daily oral medicine, if approved, to advance the standard of care for people living with acromegaly.” In addition to scientific presentations and publications, Crinetics is also sponsoring a Product Theater titled “Navigating the Complexities & Challenges of Acromegaly Management” featuring expert insights from: Dr. Elena Christofides, Chief Executive Officer, Endocrinology Associates, Inc.; Dr. Leena Shahla, Medical Director, Duke University School of Medicine; and Dr. Alan Krasner, Chief Endocrinologist, Crinetics. Crinetics e-Poster Presentations and Online Publications at AACE 2025 Title: Paltusotine in the Treatment of Surgically Naïve Patients with Acromegaly: Post Hoc Analysis of Three Clinical Trials Authors: Manoel Martins, MD, PhD et al. E-Poster Date/Time: May 17, 12:50-1:05 PM ET Location: Poster Station 15 – Learning Zone Post-hoc analysis from three clinical trials (PATHFNDR-1 [PF1], PATHFNDR-2 [PF2], and ACROBAT Advance) showed that paltusotine provided rapid and sustained insulin-like growth factor 1 (IGF-1) control in surgically naïve patients, including those who were biochemically uncontrolled at baseline. Three of four patients in PF1 and all four patients in PF2 achieved IGF-1 normalization. In Phase 3 trials patients reached IGF-1 ≤1.0x ULN, and median IGF-1 remained stable over 24 months in ACROBAT Advance. Results suggest that paltusotine may be a viable first-line medical therapy for patients for whom surgery is not an option or preference. Title: Quantitative Burden and Life Impact of Symptom Exacerbations in Patients with Medically Treated Acromegaly Authors : Eliza B. Geer, MD et al. E-Poster Date/Time: May 17, 12:50-1:05 PM ET Location: Poster Station 9 – Learning Zone In a three-month daily symptom diary study, patients receiving the long-acting injected depot somatostatin receptor ligands octreotide and lanreotide reported symptom exacerbations on 32% of days. Higher symptom burden was associated with reduced quality of life, increased urgent care utilization, and lower treatment satisfaction. Findings underscore the need for treatments that deliver more consistent acromegaly symptom control. Title: Real-world Treatment Patterns in Acromegaly Authors: Tiffany Quock, PhD, MS et al. Online publication in Endocrine Practice supplement following the annual meeting A retrospective analysis using IQVIA PharMetrics ® Plus data found that 54% of patients with acromegaly discontinued therapy during follow-up, while only 20% remained on their initial treatment. Patients who switched therapies incurred significantly higher rates of hospitalization, emergency visits, and healthcare costs. These data highlight dissatisfaction with current injectable therapies and the opportunity for further research to analyze the impact of therapies on patient outcomes. Title: Need to Pause Hydrocortisone? Physiologic Replacement Does Not Affect AM Serum Cortisol, Bedtime Salivary Cortisol or UFC in Cushing Syndrome Patients on Block and Replace Treatment Authors: Henrik Elenius, MD et al. Online publication in Endocrine Practice supplement following the annual meeting Data from a Phase 2a study of atumelnant in patients with ACTH-dependent Cushing syndrome showed that physiologic hydrocortisone doses given before 5 p.m. did not impact morning or bedtime urinary free cortisol levels. These findings support continued use of hydrocortisone during monitoring, simplifying disease management for patients. Crinetics-Sponsored Product Theater Title: Navigating the Complexities & Challenges of Acromegaly Management Date/Time: Thursday, May 15 | 7:00-7:45 AM ET The poster presentations will be made available on the Crinetics website at the time of presentation in accordance with the AACE embargo policy. About Paltusotine Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral paltusotine maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics’ second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of the PDUFA target action date for our NDA submission to the FDA and of a potential EMA decision for our MAA for paltusotine for the treatment or maintenance of treatment of acromegaly in the United States and other applicable jurisdictions, and the plans and timelines for the commercial launch paltusotine if approved; and the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics’ clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics’ drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075 Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床结果临床2期临床3期

2025-05-14

·PRNewswire

Mallinckrodt Presents Data on Real-World Outcomes with Acthar® Gel (repository corticotropin injection) at the International Congress on Systemic Lupus Erythematosus (LUPUS 2025)

– Late-breaking poster abstract highlights physician-reported treatment patterns and characteristics of patients with systemic lupus erythematosus treated with Acthar Gel1 – DUBLIN, May 14, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced a late-breaking poster abstract on Acthar® Gel (repository corticotropin injection) in patients with systemic lupus erythematosus (SLE) at the International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place in Toronto, Canada from May 21-24, 2025. Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides.1 Acthar Gel is approved by the FDA for the treatment of several autoimmune disorders and medical conditions known to cause inflammation, including during an exacerbation or as maintenance therapy in selected cases of SLE.1 Please see Important Safety Information and additional indications for Acthar Gel below. The poster abstract details a chart review from April 1, 2022, and November 2024 of 56 patients who had been treated with Acthar Gel for SLE within the prior 24 months.2 Data collected included demographics, comorbidities, symptoms, prior treatments, and health outcomes following Acthar Gel treatment.2 Results reported from this chart review included: 84% (47/56) of patients were female and 50% (28/56) were African-American2 Common comorbidities included chronic joint disease (34%, 19/56), hyperlipidemia (34%, 19/56), hypertension (34%, 19/56), and arthritis/osteoarthritis (30%, 17/56)2 Physicians reported 63% (35/56) of patients were in fair-to-poor health status prior to treatment with Acthar Gel2 The average duration of Acthar Gel treatment was 8 months, and 91% (51/56) of patients were dosed at 40-80 units twice per week2 Physicians reported that 89% (50/56) of patients experienced improved health status after Acthar Gel treatment2 This included physician-reported improvements in overall symptoms (82%, 41/50), pain (54%, 27/50), fatigue (44%, 22/50), physical function (38%, 19/50), and strength (28%, 14/50).2 A reduction in corticosteroid use (44%, 22/50) was also reported.2 "Mallinckrodt is committed to evaluating real-world treatment outcomes among those living with SLE, particularly among patient subpopulations who are disproportionally affected such as African Americans and women," said George Wan, Ph.D., M.P.H., Vice President, Evidence Generation and Data Sciences, Mallinckrodt. "This chart review provides additional data to consider when treating appropriate patients with this often difficult-to-manage disease." "This study is an example of how real-world evidence can improve our understanding of the impact of treatment for individuals affected by lupus, particularly in populations with the greatest disease burden. The Lupus Foundation of America (LFA) is grateful for the research conducted by companies like Mallinckrodt, who remain committed to advancing treatments and improving outcomes for those impacted by this disease," said Louise Vetter, President and Chief Executive Officer, Lupus Foundation of America. The limitations of this physician-reported chart review include, but are not limited to, small sample sizes, variables in methodology, and possible errors.2 Safety outcomes were not reported.2 Most patients were previously treated with other therapies and may have been using other therapies in tandem with Acthar Gel; clinical outcomes may not be solely attributable to Acthar Gel.2 This study was sponsored by Mallinckrodt Pharmaceuticals. Presentation details can be found below: Abstract #799 : TREATMENT PATTERNS AND OUTCOMES OF ACTHAR GEL IN SYSTEMIC LUPUS ERYTHEMATOSUS: A PHYSICIAN-REPORTED CHART REVIEW2 Presenter: Johanna Purcell, PhD Presentation Date: Friday May 23, 2025 through Saturday May 24, 2025 Location: Exhibition Room INDICATIONS Acthar Gel is indicated for: Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age Treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation Symptomatic sarcoidosis Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis) Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis IMPORTANT SAFETY INFORMATION Contraindications Acthar is contraindicated: For intravenous administration In infants under 2 years of age who have suspected congenital infections With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin Warnings and Precautions The adverse effects of Acthar are related primarily to its steroidogenic effects Acthar may increase susceptibility to new infection or reactivation of latent infections Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy Acthar can cause gastrointestinal (GI) bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain GI disorders. Monitor for signs of perforation and bleeding Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Acthar activity There may be an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients Decrease in bone density may occur. Bone density should be monitored in patients on long-term therapy Adverse Reactions Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased The most common adverse reactions for the treatment of infantile spasms (IS) are increased risk of infections, convulsions, hypertension, irritability, and pyrexia. Some patients with IS progress to other forms of seizures; IS sometimes masks these seizures, which may become visible once the clinical spasms from IS resolve Pregnancy Acthar may cause fetal harm when administered to a pregnant woman Please see full Prescribing Information for additional Important Safety Information. About Systemic Lupus Erythematosus (SLE) Systemic lupus erythematosus (SLE) is the most common type of lupus.3 In the United States, approximately 160,902–261,725 adults are affected by SLE.4 It is a chronic inflammatory condition that may affect joints, skin, and kidneys.5 No two cases of SLE are the same and SLE can affect people differently. Signs and symptoms can also change over time.6 There is no cure for SLE, but certain treatments may reduce symptoms and may prevent permanent damage to the body.3 About Mallinckrodt Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; and neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit . CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including with regard to Acthar® Gel, its potential to improve health and treatment outcomes, its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the effects of Mallinckrodt's recent emergence from bankruptcy; satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with Acthar Gel; and other risks identified and described in more detail in the "Risk Factors" section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. CONTACT Media Inquiries Green Room Communications 908-577-4531 [email protected] Investor Relations Bryan Reasons Executive Vice President and Chief Financial Officer [email protected] Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. ©2025 Mallinckrodt. US-2500175 05/25 References 1 Acthar® Gel (repository corticotropin injection) [prescribing information]. Bridgewater, NJ: Mallinckrodt ARD LLC. 2 Shanbhag P., Evans D., Patel. et al. Treatment Patterns and Outcomes of Acthar Gel in Systemic Lupus Erythematosus: A Physician-Reported Chart Review. Abstract: International Congress on Systemic Lupus Erythematosus (LUPUS 2025) meeting. March 2025. 3 About Lupus. Lupus Research Alliance website. what-is-lupus/about-lupus/. Accessed March 2025. 4 Izmirly P.M., Parton H., Wang L., et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. American College of Rheumatology. 2021 Jun;73(6):991-996. doi:10.1002/art.41632. 5 Symptoms. Lupus Research Alliance website. . Accessed March 2025. 6 Squance M.L., Reeves G.E., Bridgman H. The lived experience of lupus flares: features, triggers, and management in an Australian female cohort. International Journal of Chronic Diseases. 2014:1-12. SOURCE Mallinckrodt plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果上市批准

100 项与促皮质素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00146	促皮质素	H01AA01	DB01285

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膜性肾小球肾炎	加拿大	Mallinckrodt Plc	2014-12-23
脉络膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
虹膜睫状体炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
虹膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
角膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
视神经炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
后葡萄膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
强直性脊柱炎	美国	Mallinckrodt Pharmaceuticals Ireland Ltd.	1952-04-29
银屑病关节炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
皮肌炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
水肿	美国	Sanofi-Aventis U.S. LLC	1950-07-03
多形红斑	美国	Sanofi-Aventis U.S. LLC	1950-07-03
眼部疾病	美国	Sanofi-Aventis U.S. LLC	1950-07-03
幼年特发性关节炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
多发性硬化症	美国	Sanofi-Aventis U.S. LLC	1950-07-03
类风湿关节炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
结节病	美国	Sanofi-Aventis U.S. LLC	1950-07-03
血清病	美国	Sanofi-Aventis U.S. LLC	1950-07-03
婴儿痉挛	美国	Sanofi-Aventis U.S. LLC	1950-07-03
Stevens-Johnson综合征	美国	Sanofi-Aventis U.S. LLC	1950-07-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	临床3期	美国	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	阿根廷	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	加拿大	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	智利	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	哥伦比亚	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	墨西哥	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	秘鲁	Mallinckrodt Plc	2017-06-22
免疫球蛋白a肾病	临床3期	美国	Mallinckrodt Plc	2015-03-01
蛋白尿	临床3期	美国	Mallinckrodt Plc	2015-03-01
巩膜炎	临床2期	美国	Mallinckrodt Plc	2019-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02226341 (ACTHar, CTgov)	临床4期	狼疮性肾炎	8	ACTHar Gel+CellCept (CellCept Daily & ACTHar Gel BIW (Two Times Per Week))	醖築築築夢簾艱夢獵齋 = 膚築築築鹽顧廠簾廠壓襯願糧壓壓觸壓網簾鹹 (構壓繭淵淵構鹹醖糧網, 鏇構鬱壓廠壓艱蓋簾齋 ~ 淵壓積襯淵窪鏇窪製鹽) 更多	-	2025-03-07
NCT02226341 (ACTHar, CTgov)	临床4期	狼疮性肾炎	8	ACTHar Gel+CellCept (CellCept Daily & ACTHar Gel TIW (Three Times Per Week))	醖築築築夢簾艱夢獵齋 = 製範醖鏇顧鑰網觸膚繭襯願糧壓壓觸壓網簾鹹 (構壓繭淵淵構鹹醖糧網, 蓋鹽顧鹽獵夢窪網糧艱 ~ 夢壓壓積鏇觸觸憲鏇觸) 更多	-	2025-03-07
ENDO2024	N/A	转移性宫颈癌 Ki-67 \| vimentin \| CEA ... 更多	-	Chemotherapy and radiotherapy	築夢繭鑰夢鹹醖願壓觸(夢鏇觸願鏇鬱餘淵遞鹹) = 繭遞廠膚齋夢願範憲餘艱構製顧鏇廠構範艱糧 (壓願壓鏇構淵積觸膚廠 ) 更多	不佳	2024-06-01
ENDO2024	N/A	转移性宫颈癌 Ki-67 \| vimentin \| CEA ... 更多	-	Etomidate infusion	築夢繭鑰夢鹹醖願壓觸(夢鏇觸願鏇鬱餘淵遞鹹) = 鬱鑰鬱顧淵鏇淵網製積艱構製顧鏇廠構範艱糧 (壓願壓鏇構淵積觸膚廠 ) 更多	不佳	2024-06-01
NCT03021317 (ACTHAR, CTgov)	临床4期	多发性硬化症	5	ACTHar	廠艱獵選蓋範繭艱鬱積(築製簾餘淵鑰窪積淵鹹) = 壓窪壓製廠蓋糧壓醖鑰製壓淵簾鏇製衊襯糧壓 (鹹鏇簾窪鬱繭網繭夢齋, 艱鹽鹹襯鹽窪鏇築遞積 ~ 餘積鹹鏇艱繭蓋膚齋淵) 更多	-	2024-05-16
Biospace 人工标引	N/A	结节病	272	Acthar (African American (AA))	範蓋繭憲積構鹽鑰壓鏇(壓膚願遞範壓膚顧繭鹹) = 襯壓鹹壓獵積願淵糧夢簾衊鑰鹽願鏇蓋顧觸鏇 (鏇觸範夢範鑰淵鬱襯糧 ) 更多	积极	2024-03-11
Biospace 人工标引	N/A	结节病	272	Acthar (non-African American (non-AA))	範蓋繭憲積構鹽鑰壓鏇(壓膚願遞範壓膚顧繭鹹) = 淵鹹遞遞鑰鹹餘鑰齋壓簾衊鑰鹽願鏇蓋顧觸鏇 (鏇觸範夢範鑰淵鬱襯糧 ) 更多	积极	2024-03-11
NCT01906372 (Pubmed \| Rheumatology (Oxford))	临床2期	皮肌炎	19	Repository corticotropin injection (RCI) 80 u	齋繭鏇繭鹹襯糧範糧鑰(襯鏇齋顧願壓夢鬱襯艱) = 觸夢構繭獵網糧廠襯艱餘艱鏇壓選鏇遞簾簾鑰 (糧醖醖夢簾廠築壓襯願 ) 更多	积极	2023-11-06
ESPE2023	N/A	-	28	High dose oral synthetic glucocorticoids	壓繭願蓋獵觸願選膚鬱(衊窪鏇齋蓋網製憲艱鑰) = 窪廠顧醖窪網獵廠鏇構襯餘顧製壓鹹網齋鏇淵 (壓窪襯窪淵膚壓簾膚鏇 ) 更多	-	2023-09-21
NCT02030028 (CTgov)	N/A	类风湿关节炎	18	ACTHAR gel	鹽網鏇觸醖壓鏇鹽鏇範 = 齋餘糧衊觸襯夢壓醖齋艱膚選蓋繭襯齋憲積膚 (蓋齋壓廠製構顧遞艱鹽, 範鑰繭鑰壓遞衊鹽窪製 ~ 繭鹽願積網餘簾網艱選) 更多	-	2023-09-06
ARVO2023	N/A	边缘干细胞缺乏症	4	Acthar Gel	築衊淵簾獵築簾構網夢(顧觸觸廠鹽餘鹹鹽齋膚) = 壓窪齋齋襯餘選膚鹽製齋齋鏇築膚遞鹹鹽鏇壓 (艱蓋窪憲製夢獵繭積鏇 )	积极	2023-04-23
NCT02725177 (CTgov)	N/A	前葡萄膜炎 \| 结节病	9	Repository Corticotropin Injection -Treatment Extension	範廠襯構簾壓繭網願獵 = 繭鏇顧壓衊鹽膚顧獵網選簾願壓夢構鏇鹽窪鬱 (餘糧選鹽顧顧網選觸願, 襯鹹構築範製鏇簾淵窪 ~ 鬱鏇鹽憲顧廠醖齋簾鑰) 更多	-	2023-02-15
PSAT041 (ENDO2022)	N/A	库欣综合征	-	Lanreotide	鬱選鹽願願醖醖廠糧簾(糧窪膚艱簾顧醖鹹蓋簾) = 糧艱繭簾糧鬱膚構獵鹽淵壓築觸淵獵蓋觸襯築 (獵艱衊願鑰簾夢夢壓廠 ) 更多	-	2022-11-01